This review examined the effects of efpeglenatide on glycemic control, weight reduction, and cardiovascular outcomes as well as its safety profile compared with those of placebo and other GLP-1 RAs to establish its role in comprehensive metabolic and diabetes management. This evidence concerns the gene GLP1R and diabetes mellitus.